Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% – What’s Next?

by · The Cerbat Gem

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) fell 3.7% on Thursday . The stock traded as low as $0.32 and last traded at $0.35. 51,497,243 shares were traded during mid-day trading, an increase of 103% from the average session volume of 25,332,580 shares. The stock had previously closed at $0.36.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Sunday, December 15th. They set a “sell” rating on the stock.

Get Our Latest Stock Analysis on TNXP

Tonix Pharmaceuticals Price Performance

The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average price is $0.20 and its two-hundred day moving average price is $0.49. The stock has a market capitalization of $114.30 million, a PE ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Read More